The observation that IGFBP2 is hypermethylated in lung and liver cancers is somewhat surprising as elevated plasma levels have been described for these diseases (57, 87); however, the higher plasma levels of IGFBP2 may represent a systemic response to cancer, or the confounding factors described above. Here, IGFBP2 is linked to cancer.